Neko Health has secured $700 million in new funding to accelerate the expansion of its AI-powered preventive health screening services in the United States. The company plans to launch its first American clinic in New York before expanding into additional cities.
The healthcare technology company combines advanced medical imaging, blood testing, proprietary sensors, artificial intelligence, and clinician-led consultations into a single preventive health assessment. Its goal is to help individuals identify potential health risks early, before symptoms appear.
The latest investment round highlights growing interest in AI-driven healthcare and preventive screening technologies as investors continue to back innovative approaches to health monitoring and disease prevention.
Neko Health Secures $700 Million in Series C Funding
The funding came through a Series C round led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. Existing investors Atomico, General Catalyst, and Lakestar also participated in the round, while new investors included Liberty City Ventures, Positive Sum, and BDT & MSD.
As part of the investment, David Ofer of O.G. Venture Partners is expected to join Neko Health’s board of directors, subject to regulatory approval.
The latest raise pushes Neko Health’s disclosed funding beyond $1 billion since 2023. The company previously raised $65 million in a Series A round in 2023 and secured another $260 million in January 2025.
This substantial financial backing reflects strong confidence in Neko Health’s long-term vision for preventive healthcare powered by artificial intelligence and advanced medical technology.
High-Profile Investors Back Neko Health
The funding round attracted several well-known investors from technology, entertainment, and sports.
Among the individual investors participating in the round were:
- Meta CEO Mark Zuckerberg and Priscilla Chan
- Former tennis star Maria Sharapova
- Musician and entrepreneur will.i.am
- Former football player Thierry Henry
Existing individual investors include Reddit co-founder Alexis Ohanian and actress Zoë Saldaña.
The participation of these high-profile investors demonstrates increasing interest in preventive healthcare solutions that use technology to improve early disease detection and long-term health management.
How Neko Health’s AI Body Scan Works
Neko Health operates clinics that combine full-body scanning technology, blood testing, artificial intelligence, and proprietary medical devices into a comprehensive health assessment.
The service is designed to identify possible indicators of health conditions such as:
- Skin cancer
- Cardiovascular disease
- Diabetes
- Metabolic syndrome
- Stroke risk
- Heart attack risk
According to the company, the screening process is non-invasive, radiation-free, and takes approximately 60 minutes to complete.
Customers receive a detailed review of their health data through a combination of automated analysis and clinician evaluation.
What Happens During a Neko Health Scan?
The health assessment includes a broad range of measurements and diagnostic screenings.
Neko Health evaluates:
- Skin conditions
- Blood abnormalities
- Indicators of pre-diabetes
- Cardiovascular risk factors
- Metabolic health markers
The scan also includes:
- Electrocardiogram (ECG) testing
- Arterial measurements
- Body composition analysis
- High-resolution skin imaging
One of the most distinctive features of the service is the use of more than 2,000 high-resolution images to create a detailed map of a customer’s skin.
Blood samples are processed on-site, enabling results to be reviewed during the same appointment. Customers then meet with a healthcare professional who discusses the findings and recommends any necessary follow-up actions.
How Neko Combines Multiple Health Tests Into One Appointment
Many of the measurements included in a Neko Health scan are already available through traditional healthcare services. These include blood pressure checks, cholesterol testing, blood glucose measurements, ECG assessments, and skin examinations.
What sets Neko apart is its ability to bring these assessments together in a single appointment while combining them with proprietary imaging systems, automated data collection, on-site blood analysis, and clinician consultations.
The company presents this integrated approach as a more convenient way for individuals to access preventive healthcare.
However, publicly available clinical materials reviewed for this article do not include comparative studies demonstrating whether the combined approach improves clinical outcomes or cost-effectiveness compared with traditional preventive care pathways.
Neko Health Plans Major Expansion in the United States
The newly raised capital will support the company’s expansion throughout the US market.
Neko Health has confirmed plans to open clinics in New York and additional American cities. While New York will be the first location, the company has not yet revealed where future clinics will be established.
A waitlist for the New York clinic is already available through the company’s website.
At the time of the announcement, Neko Health had not disclosed pricing for its US-based scans.
Current Neko Health Clinic Locations
Neko Health currently operates eight clinics across Sweden and the United Kingdom.
Its clinic network includes:
Sweden
- Two clinics in Stockholm
United Kingdom
- Manchester
- Birmingham
- London Marylebone
- London Spitalfields
- London Covent Garden
- London Victoria
The current pricing structure is:
- £299 per scan in the United Kingdom
- 2,750 Swedish kronor per scan in Sweden
These prices are approximately equivalent to $400 and $285 respectively.
Neko Health Growth Since Launch
Since launching its preventive health screening service in 2023, Neko Health has experienced rapid growth.
According to the company:
- More than 100,000 scans have been completed
- Over 350,000 people have either registered for a scan or joined waiting lists
The company also reports strong customer retention. Neko says that approximately 75% of customers book and prepay for another scan before leaving their appointment.
This recurring model allows clinicians to compare health data over time, helping track changes in measurements and skin imaging results.
However, publicly available information does not establish whether annual screenings are the most appropriate interval for every age group or health-risk category.
Founded by Spotify Co-Founder Daniel Ek
Neko Health was founded in 2018 by Spotify co-founder Daniel Ek and chief executive Hjalmar Nilsonne.
The company spent several years developing its technology and infrastructure before publicly launching its healthcare service in 2023.
Since then, it has become one of the most closely watched startups in the preventive healthcare sector.
Nilsonne stated that a portion of the newly raised capital will be used to support additional research and development focused on preventive screening technologies.
New Medical Devices and Technology Upgrades
Neko Health continues to expand its proprietary technology platform.
The company recently introduced:
- Body composition measurements
- Clinician reviews of wearable-device data
It has also released updated versions of its Derma, Echo, and Spectrum medical devices.
Derma
Designed to collect skin-related health information.
Echo
Focused on monitoring heart function.
Spectrum
Used to assess circulation and cardiovascular health indicators.
According to Neko, the updated devices gather larger volumes of health information and automate additional parts of the scanning process.
The company plans to deploy the new equipment across its clinic network in the coming months.
Neko Health’s Clinic-Based Healthcare Model
Unlike digital-only healthcare platforms, Neko Health relies heavily on physical infrastructure.
Its clinics require:
- Proprietary medical equipment
- Blood-processing facilities
- Medical professionals
- Specialist clinical review teams
Neko says its seven-room Covent Garden clinic was designed to support tens of thousands of scans each year. However, the company has not disclosed capacity figures or staffing plans for its future US locations.
FDA Clearance Supports US Expansion
As Neko Health prepares to enter the US market, regulatory approvals have become increasingly important.
FDA records show that two internally developed devices received clearance through the agency’s 510(k) pathway in May 2026.
These include:
Derma-2
Cleared as an adjunctive telethermographic system.
Spectrum-2
Cleared as a tissue-saturation oximeter used in cardiovascular measurements.
The FDA clearances apply specifically to these devices and their intended uses. They do not represent approval of the complete Neko Health Scan as a single screening service.
Insurance Coverage and Customer Costs
Neko Health describes its US clinics as providers of preventive health and wellness services rather than full-service medical practices.
The company advises customers to continue working with their existing healthcare providers for diagnosis and treatment, including any conditions identified during a Neko scan.
When findings require further evaluation, specialist clinicians such as dermatologists and cardiologists review the results.
Customers may receive:
- Follow-up appointments
- Referral letters
- Introductions to external healthcare specialists
At present, Neko’s US clinics do not participate in health insurance plans, and most services are not covered by insurance providers.
Customers are therefore expected to pay directly for their initial assessment.
The company has not announced:
- US pricing
- Costs of external diagnostic tests
- Costs of treatment provided by outside healthcare organizations
- Potential employer or insurer subsidies
Questions Remain About Clinical Evidence
Despite strong investor support and growing consumer interest, questions remain regarding the scientific evidence supporting Neko Health’s screening model.
Publicly available information does not include a completed peer-reviewed study validating the entire Neko Health Scan service.
A study registered on ClinicalTrials.gov is currently evaluating the company’s multimodal skin-imaging technology for screening and diagnostic-support applications, including skin cancer and Raynaud’s phenomenon.
However, the study remains ongoing and does not establish the effectiveness of the complete screening platform.
False Positives and Follow-Up Procedures
Public materials reviewed for this article do not disclose several important performance metrics, including:
- False-positive rates
- Numbers of customers undergoing additional procedures
- Frequency of clinically insignificant findings
As a result, independent assessment of the overall screening service remains limited.
The Role of Artificial Intelligence in Neko Health
Artificial intelligence plays a role in Neko Health’s workflow, although public information provides limited detail regarding specific AI functions.
According to the company’s US privacy notice, an AI-powered dictation system helps:
- Summarize medical records
- Process questionnaires
- Analyze scan information
- Summarize clinical conversations
- Draft reports
Neko states that clinicians review reports generated through the system before they are finalized.
Public information does not fully explain which scan measurements or classifications depend on AI, conventional software, or direct clinical assessment.
The company also does not state that AI independently diagnoses medical conditions.
Similarly, FDA clearances for individual devices do not validate every algorithm used to combine or interpret the collected health data.
Early Health Outcome Data From Repeat Customers
Neko Health has reported health outcome data based on 1,469 customers who completed a second scan approximately one year after their first appointment.
According to the company, these customers showed improvements in:
- Blood pressure
- Cholesterol levels
- Blood sugar measurements
Body weight remained relatively stable.
The data came from customers who visited Neko’s Stockholm clinics and were categorized into several groups, including healthy individuals, customers with hypertension, pre-diabetes, and diabetes.
However, Neko acknowledges that the analysis was not a scientific study and did not include a control group.
Customers may have changed their lifestyle habits or started medical treatments between scans, meaning the results do not prove that the scans themselves caused the improvements.
The analysis also focused only on customers who purchased a second scan, and the company did not publish demographic data comparing this group with its broader customer base or the general population.
Neko Health Valuation and Future Outlook
Neko Health did not disclose its valuation following the latest funding round. However, the Financial Times reported, citing unnamed sources, that the company is now valued at approximately $7 billion.
With more than $1 billion raised since 2023, over 100,000 completed scans, and plans to expand throughout the United States, Neko Health is positioning itself as a major player in the growing preventive healthcare market.
While further clinical research will be needed to determine the long-term impact of its AI-powered screening model, the company’s rapid growth, significant funding, and international expansion plans suggest strong momentum in the evolving field of preventive health technology.
Discover more from AiTechtonic - Informative & Entertaining Text Media
Subscribe to get the latest posts sent to your email.